Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30137% above fair value
$25.63−0.34 (-1.31%)
Close on Nov 18, 2026Market cap $983.63MP/E –Yield –
Ceribell gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Ceribell's gross profit for the twelve months ending Jun 30, 2026 was $90.65M, up 33.4% year over year. For fiscal 2025 it was $78.27M, up 37.9% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.27M | +37.9% |
| FY2024 | Dec 31, 2024 | $56.75M | +48.7% |
| FY2023 | Dec 31, 2023 | $38.16M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $25.94M | +38.8% |
| Q1 FY2026 | Mar 31, 2026 | $23.12M | +28.4% |
| Q4 FY2025 | Dec 31, 2025 | $21.64M | +33.3% |
| Q3 FY2025 | Sep 30, 2025 | $19.94M | +32.8% |
| Q2 FY2025 | Jun 30, 2025 | $18.68M | +42.0% |
| Q1 FY2025 | Mar 31, 2025 | $18.01M | +45.9% |
| Q4 FY2024 | Dec 31, 2024 | $16.24M | +46.1% |
| Q3 FY2024 | Sep 30, 2024 | $15.01M | +54.3% |
| Q2 FY2024 | Jun 30, 2024 | $13.16M | – |
| Q1 FY2024 | Mar 31, 2024 | $12.34M | – |
| Q4 FY2023 | Dec 31, 2023 | $11.12M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.73M | – |
See a number that looks wrong?